Currently out of the existing stock ratings of Christopher Liu, 14 are a BUY (77.78%), 4 are a HOLD (22.22%).

Christopher Liu

Work Performance Price Targets & Ratings Chart

Analyst Christopher Liu, currently employed at LUCID CAPITAL, carries an average stock price target met ratio of 36.11% that have a potential upside of 20.38% achieved within 119 days. Previously, Christopher Liu worked at LEERINK.

Christopher Liu’s has documented 36 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IPHA, Innate Pharma at 23-Oct-2025.

Wall Street Analyst Christopher Liu

Analyst best performing recommendations are on LYEL (LYELL IMMUNOPHARMA).
The best stock recommendation documented was for COGT (COGENT BIOSCIENCES) at 6/10/2022. The price target of $15 was fulfilled within 68 days with a profit of $7.13 (90.6%) receiving and performance score of 13.32.

Average potential price target upside

of $7.06 (72.17%) on COGT (COGENT BIOSCIENCES).

COGT Cogent Biosciences NRIX Nurix Therapeutics ARVN Arvinas IDYA Ideaya Biosciences EXEL Exelixis ADAG Adagene CCCC C4 Therapeutics IPHA Innate Pharma LYEL Lyell Immunopharma

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

David Nierengarten (WEDBUSH)